

About	
Products	
Pipeline	
Research and Development	
Regenerative medicine	
Pre-clinical and clinical trials	
Manufacturing & QA	
Partners	
Work for us	
Contact us	
News	

Elizaria®

[All products](#)

INN: Eculizumab

A humanized monoclonal antibody that binds to the human complement protein C5 and inhibits the activation of complement-mediated cytolysis.



Elizaria® inhibits the activation of the terminal complement cascade, thereby regulating complement activity in the blood.

Elizaria® prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as excessive activation of the complement complex in patients with atypical hemolytic uremic syndrome (aHUS).

Eculizumab treatment in patients leads to a significant decrease in the risk of thrombosis, dependence on blood transfusion in patients with hemoglobinuria, and also significantly improves renal function in patients with atypical hemolytic uremic syndrome.

Indications for use:

- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)

GENERIUM is the only company in the world that has developed biosimilar of Eculizumab.

Main office

10, ent. 2, Testovskaya st., Moscow,
123112, Russia
Tel: +7 495 988-47-94
Generium@Generium.ru

About

Careers

Our products

Coagil-VII®
Octofactor®
Innonafactor®
Diaskintest®
Infibeta®
T-SPOT®.TB
Tigerase®
Elizaria®
Glurazyme®
Revelise®

All rights reserved. Generium 2019



Site development — **AGIMA**

Tech support — **Techart.**